ASTX727 delivers superior response rates and associated survival benefit versus hydroxycarbamide/best supportive care in CMML and other MDS/MPN overlap syndromes: First results from the Phase 2 UK multicenter randomized ammo trial
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-488
Abstract: Background Chronic myelomonocytic leukemia (CMML) and the rarer MDS/MPN overlap syndromes share biological features, poor prognosis (median survival 60%) CMML. Most were higher-risk by CPSS-Mol/IPSS-R; 73% had proliferative disease mandating cytoreduction. Arms were well balanced… read more here.
Keywords: response; cmml; mds mpn; astx727 ... See more keywords